ViroCell Appoints Brian Collins as CFO
Retrieved on:
Wednesday, July 26, 2023
Professional Services, Health, Genetics, Finance, Clinical Trials, Biotechnology, GMP, LSE, Risk, Oxford Biomedica, Gene, Great Ormond Street Hospital for Children NHS Foundation Trust, B2B, Avery Dennison, Organic, Doctor of Philosophy, OXB, CDMO, Cell, HR, H.B. Fuller, CFO, Growth, Great Ormond Street Hospital, Operational excellence, Non-executive director, Pharmaceutical industry, Management, Vaccine
ViroCell Biologics (“ViroCell” or the “Company”), a specialist Contract Development and Manufacturing Organisation (“CDMO”) in cell and gene therapy clinical trials, announces the appointment of Brian Collins as Chief Financial Officer (“CFO”).
Key Points:
- ViroCell Biologics (“ViroCell” or the “Company”), a specialist Contract Development and Manufacturing Organisation (“CDMO”) in cell and gene therapy clinical trials, announces the appointment of Brian Collins as Chief Financial Officer (“CFO”).
- John W. Hadden II, CEO at ViroCell, commented, “I am delighted to welcome Brian to the ViroCell team.
- Prior to the CGT Catapult, Brian was the CFO of Coveris Packaging and before that held numerous financial and operational roles of increasing seniority at companies, including MSX International, HB Fuller and Avery Dennison.
- Throughout his 30-year career in finance, Brian has built finance operations, led acquisitions, and secured company financings.